Jefferies assumed coverage of Acrivon Therapeutics with a Buy rating and a price target of $12, down from $17. The firm sees platform value from the company’s proteomic based screening platform calleld AP3 and the OncoSignature test to predict patient responders and believes the lead oncology program, ACR-368, has potential to provide near-term upside if OncoSignature successfully predicts responders, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACRV:
- Acrivon Therapeutics files $300M mixed securities shelf
- Acrivon Therapeutics announces FDA has granted BDD for ACR-368
- Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
- Acrivon Therapeutics announces inducement grant under Nasdaq listing rule
